Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

Females are twice as likely to get oral lichen planus compared to men. Since the reason for this condition is still unknown, there is no known way to prevent the condition. Although there is no ...

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

It indicates that the relevant content has been reviewed and verified by an expert Our stories are reviewed by medical professionals to ensure you get ... oral thrush. 3. Oral Lichen Planus ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

LP-310 is being developed as a non-steroidal, locally delivered treatment for oral lichen planus, a chronic inflammatory condition with no FDA-approved therapies.

Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0 ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...